Yep, agree with all of the above. This why you need a second (and third and fourth) indication. You need a pipeline of studies and/or products to de-risk and create value for shareholders. Even if this means we get diluted along the way, raising money to fund these other indications - we're still better off on the other side. A small % of something is better than a larger % of nothing. IXC need to hold a conference call to discuss the announcement - they need to front up.
Ann: Phase III Clinical Trial Update and New IIH Market Analysis, page-85
-
- There are more pages in this discussion • 140 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IXC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
7.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $5.335M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 532 | 7.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 7.5¢ | 8695 | 1 |
View Market Depth
| Last trade - 16.12pm 09/08/2024 (20 minute delay) ? |
| IXC (ASX) Chart |
Day chart unavailable